Summary

The vaccines market (excluding COVID-19) is expected to reach USD 71.14 billion in 2031, up from USD 55.68 billion in 2026, growing at a CAGR of 5.0% during the forecast period. Factors such as the high incidence of contagious diseases, innovation in vaccine technology, government support and substantial funding for vaccine development, increasing vaccination initiatives, and a strong focus on investing in and launching innovative products are driving this growth in vaccines.

By disease indication, the pneumococcal segment accounted for the largest share of the vaccines market in 2025.
Based on disease indication, the vaccines market is segmented into combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, pneumococcal disease, influenza, varicella, hepatitis, DTP, polio, COVID-19, and other disease indications. In 2025, the pneumococcal segment held the largest share of the vaccines market. This is due to several key factors: a rising incidence of pneumococcal infections worldwide; increased government funding for vaccination programs; and heightened public awareness of the serious health risks associated with pneumococcal-related complications such as pneumonia, meningitis, and bloodstream infections. Additionally, ongoing innovation and the development of next-generation pneumococcal vaccines, such as the recently approved 20-valent and 21-valent conjugate vaccines, are expanding immunization options, further boosting market growth and public health benefits.

By type, the multivalent vaccines segment accounted for the largest share of the vaccines market in 2025.
The vaccines market is divided into monovalent vaccines and multivalent vaccines, based on type. In 2025, the multivalent vaccines segment held the largest portion of the Vaccines market. This dominance stems from multivalent vaccines' ability to protect against multiple diseases with a single dose—simplifying immunization by reducing the number of injections needed, which increases patient compliance and decreases logistical challenges. Additionally, the growing prevalence of diseases that require broad-spectrum immunity, such as respiratory infections and certain cancers, has increased demand for these vaccines. Further supporting this trend are technological advances and increased investment in efficient manufacturing of multivalent vaccines, enabling larger and faster production. Governments and healthcare providers in regions with limited healthcare access particularly favor them because simplified vaccination schedules improve coverage and boost public health outcomes.
The Asia Pacific region is expected to grow at the highest CAGR in the vaccines market from 2026 to 2031.
The vaccines market region is divided into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific region is expected to grow at a significant CAGR during the forecast period. This increase is driven by greater public health awareness, expanding national immunization programs, and increased government investment in healthcare infrastructure. Supporting these efforts are public–private partnerships, international collaborations aimed at improving vaccine equity, and technological advancements that enable advanced vaccine development and more affordable production. Additionally, the region’s large and growing populations, especially in countries such as China and India, present a substantial target market for both established and new vaccines. These factors highlight the Asia Pacific’s leadership in the vaccine industry market.
The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side (80%) and Demand Side (20%)
• By Designation: Managers (45%), CXOs and Directors (30%), and Executives (25%)
• By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)

Pfizer, Inc. (US), GSK Plc (UK), Merck & Co., Inc. (US), Sanofi (France), CSL (Australia), Emergent (US), Johnson & Johnson Services Inc. (US), AstraZeneca (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company, Limited (Japan), Panacea Biotec (India), Biological E. Limited (India), Bharat Biotech (India), Novavax (US), Inovio Pharmaceuticals (US), Sinovac (China), Incepta Pharmaceuticals (Bangladesh), Valneva SE (France), VBI Vaccines Inc. (US), Bio Farma (Indonesia), FSUE NPO Microgen (Russia), Zhi Fei Biological (China), and Indian Immunologicals Ltd. (India) are some of the key companies offering vaccines.

Research Coverage
This research report categorizes the vaccines market by technology (conjugate vaccines, recombinant vaccines, inactivated & subunit vaccines, live attenuated vaccines, toxoid vaccines, and other vaccines), type (monovalent vaccines and multivalent vaccines), indication (pneumococcal disease, influenza, combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, varicella, hepatitis, DTP, polio, RSV, COVID-19, and other disease indications), route of administration (intramuscular & subcutaneous administration, oral administration, and other routes of administration), end user (pediatric vaccines and adult vaccines), and region (North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa).
The scope of the report provides detailed information on major factors such as drivers, challenges, opportunities, and restraints that influence the growth of the vaccines market. A comprehensive analysis of key industry players has been conducted to offer insights into their business overview, product portfolios, and key strategies, including collaborations, partnerships, expansions, agreements, acquisitions, and recent developments related to the vaccines market. This report includes a competitive analysis of top players and upcoming startups within the vaccines market ecosystem. The report also details primary factors like drivers, restraints, challenges, and opportunities shaping the market growth, along with an in-depth review of key industry players’ solutions, products, recent product launches, mergers, acquisitions, and emerging market trends ecosystem.

Key Benefits of Buying the Report
This report offers a comprehensive overview of the vaccines market. It aims to assess the size and future growth opportunities of the market across various segments, such as technology, type, indication, route of administration, end user, and region. The report also features an in-depth competitive analysis of the major market players, including their company profiles, recent developments, and key market strategies.
The report provides insights into the following pointers:
Analysis of key drivers (focus on vaccine development and launches, rising prevalence of infectious diseases, increasing immunization programs, advancements in vaccine technology, and government support & funding for vaccine development), restraints (high cost of vaccine development), opportunities (rising focus on therapeutic vaccines, extensive R&D for vaccines, and increased investments in clinical trials), and challenges (stringent regulatory processes and product recalls)
• Product Development/Innovation: Detailed insights on newly launched products and technological assessment of the vaccines market.
• Market Development: Comprehensive information about lucrative markets; the report analyzes the vaccines market across varied regions.
• Market Diversification: Exhaustive information about new, untapped geographies, recent developments, and investments in the vaccines market
Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as GSK plc (UK), Merck & Co., Inc. (US), Pfizer, Inc. (US), Sanofi (France), CSL (Australia), Emergent (US), Johnson & Johnson Services Inc. (US), AstraZeneca (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company, Limited (Japan), Panacea Biotec (India), Biological E. Limited (India), Bharat Biotech (India), Novavax (US), Inovio Pharmaceuticals (US), Sinovac (China), Incepta Pharmaceuticals (Bangladesh), Valneva SE (France), VBI Vaccines Inc. (US), Bio Farma (Indonesia), FSUE NPO Microgen (Russia), Zhi Fei Biological (China), and Indian Immunologicals Ltd (India), among others, in the vaccines market.
The report also helps stakeholders understand the trends of the vaccines market and provides information on key market drivers, restraints, challenges, and opportunities. A detailed analysis of key industry players has been conducted to offer insights into their key strategies, product launches and approvals, pipeline developments, acquisitions, partnerships, collaborations, recent activities, investments and funding, brand and product comparisons, vendor evaluations, and financial metrics of the vaccines market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 39
1.1 STUDY OBJECTIVES 39
1.2 MARKET DEFINITION 39
1.3 STUDY SCOPE 40
1.3.1 MARKET SEGMENTATION & REGIONS COVERED 40
1.3.2 INCLUSIONS & EXCLUSIONS 41
1.3.3 YEARS CONSIDERED 41
1.3.4 CURRENCY CONSIDERED 42
1.4 STAKEHOLDERS 42
1.5 SUMMARY OF CHANGES 42
2 EXECUTIVE SUMMARY 44
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 44
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 46
2.3 DISRUPTIVE TRENDS IN VACCINES MARKET 47
2.4 HIGH-GROWTH SEGMENTS 48
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 49
3 PREMIUM INSIGHTS 51
3.1 VACCINES MARKET OVERVIEW 51
3.2 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE AND COUNTRY, 2025 52
3.3 VACCINES MARKET (EXCLUDING COVID-19 VACCINES): GEOGRAPHIC GROWTH OPPORTUNITIES 53
3.4 VACCINES MARKET (EXCLUDING COVID-19 VACCINES) SHARE, BY ROUTE OF ADMINISTRATION, 2026 VS 2031 (%) 54
4 MARKET OVERVIEW 55
4.1 INTRODUCTION 55
4.2 MARKET DYNAMICS 55
4.2.1 DRIVERS 56
4.2.1.1 Focus on vaccine development and launches 56
4.2.1.2 Rising prevalence of infectious diseases 58
4.2.1.3 Increasing immunization programs 59
4.2.1.4 Advancements in vaccine technology 60
4.2.1.5 Government support and funding for vaccine development 61
4.2.2 RESTRAINTS 62
4.2.2.1 High cost of vaccine development 62
4.2.3 OPPORTUNITIES 64
4.2.3.1 Rising focus on therapeutic vaccines 64
4.2.3.2 Extensive R&D for vaccines and increased investments in clinical trials 67
4.2.4 CHALLENGES 67
4.2.4.1 Stringent regulatory processes 67
4.2.4.2 Product recalls 68
4.3 UNMET NEEDS & WHITE SPACES 69
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 70
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 70
5 INDUSTRY TRENDS 72
5.1 PORTER’S FIVE FORCES ANALYSIS 72
5.1.1 BARGAINING POWER OF SUPPLIERS 73
5.1.2 BARGAINING POWER OF BUYERS 73
5.1.3 THREAT OF NEW ENTRANTS 73
5.1.4 THREAT OF SUBSTITUTES 73
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 74
5.2 MACROECONOMIC OUTLOOK 74
5.2.1 INTRODUCTION 74
5.2.2 GDP TRENDS & FORECAST 74
5.2.3 TRENDS IN GLOBAL VACCINES INDUSTRY 75
5.3 VALUE CHAIN ANALYSIS 76
5.4 PIPELINE ANALYSIS 77
5.4.1 VACCINES MARKET: CLINICAL TRIALS, BY PHASE 77
5.4.2 VACCINES MARKET: CLINICAL TRIALS, BY DISEASE INDICATION 77
5.4.3 VACCINES MARKET: PHASE 2/3 CLINICAL TRIALS, BY COMPANY 81
5.5 ECOSYSTEM ANALYSIS 83
5.6 PRICING ANALYSIS 85
5.6.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2024–2026 86
5.6.2 AVERAGE SELLING PRICE TREND, BY DISEASE INDICATION, 2024–2026 88
5.6.3 AVERAGE SELLING PRICE TREND, BY REGION, 2022–2024 89
5.7 TRADE ANALYSIS 91
5.7.1 IMPORT SCENARIO (HS CODE 300220) 91
5.7.2 EXPORT SCENARIO (HS CODE 300220) 93
5.8 KEY CONFERENCES AND EVENTS, 2026–2027 94
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS 95
5.10 INVESTMENT AND FUNDING SCENARIO 96
5.10.1 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE 97
5.11 IMPACT OF 2025 US TARIFFS—VACCINES MARKET 98
5.11.1 INTRODUCTION 98
5.11.2 KEY TARIFF RATES 98
5.11.3 PRICE IMPACT ANALYSIS 99
5.11.4 IMPACT ON COUNTRIES/REGIONS 99
5.11.4.1 US 99
5.11.4.2 Europe 100
5.11.4.3 Asia Pacific 100
5.11.5 IMPACT ON END-USE INDUSTRIES 100
5.11.5.1 Public health & government bodies 100
5.11.5.2 Healthcare providers & institutions 101
5.12 VACCINE PROCUREMENT DATA 101
5.12.1 NUMBER OF VACCINES DELIVERED BY UNICEF, 2024–2026 101
5.12.2 WHO: VACCINE PURCHASE DATABASE, 2022–2024 102
5.13 VACCINE MANUFACTURING PROCESS 104
5.13.1 OVERVIEW 104
5.13.1.1 R&D and process development 104
5.13.1.2 Upstream production (antigen generation) 105
5.13.1.3 Downstream processing 105
5.13.1.4 Formulation & fill-finish 105
5.13.1.5 Quality control & regulatory release 105
5.13.1.6 Packaging, cold chain, and distribution 105
5.13.2 MANUFACTURING MODELS & CAPACITY DYNAMICS 105
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, AND INNOVATIONS 108
6.1 TECHNOLOGY ANALYSIS 108
6.1.1 KEY EMERGING TECHNOLOGIES 108
6.1.1.1 Recombinant technology 108
6.1.1.2 Conjugation technology 108
6.1.1.3 Viral vector technology 109
6.1.2 COMPLEMENTARY TECHNOLOGIES 109
6.1.2.1 Encapsulation & delivery technology 109
6.1.2.2 Automation & control 109
6.1.2.3 AI & machine learning for vaccine design 110
6.1.3 ADJACENT TECHNOLOGIES 110
6.1.3.1 Single-use technology 110
6.1.3.2 Cell line development 110
6.2 TECHNOLOGY/PRODUCT ROADMAP 111
6.3 PATENT ANALYSIS 111
6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR VACCINE PATENTS 112
6.4 FUTURE APPLICATIONS 114
6.5 IMPACT OF AI/GEN AI—VACCINES MARKET 115
6.5.1 BEST PRACTICES IN VACCINES WORKFLOW 116
6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN VACCINES MARKET 117
6.5.3 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS 117
6.5.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN VACCINES MARKET 118
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 119
7.1 REGIONAL REGULATIONS AND COMPLIANCE 119
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 119
7.1.2 REGULATORY FRAMEWORK 122
7.1.2.1 North America 122
7.1.2.2 Europe 122
7.1.2.3 Asia Pacific 123
7.1.2.4 Latin America 123
7.1.2.5 Middle East & Africa 123
7.1.3 REGULATORY CHALLENGES IN VACCINES MARKET 124
7.1.4 INDUSTRY STANDARDS 124
7.2 SUSTAINABILITY INITIATIVES 125
7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY 125
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 126
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 127
8.1 DECISION-MAKING PROCESS 127
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 127
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 127
8.2.2 KEY BUYING CRITERIA, BY END USER 129
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 130
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 131
8.5 MARKET PROFITABILITY 131
9 VACCINES MARKET, BY DISEASE INDICATION 132
9.1 INTRODUCTION 133
9.2 PNEUMOCOCCAL DISEASE 134
9.2.1 EXPANDING ADULT IMMUNIZATION PROGRAMS AND HIGHER-VALENCY VACCINES TO DRIVE MARKET 134
9.3 INFLUENZA 138
9.3.1 SEASONAL IMMUNIZATION PROGRAMS AND EXPANDING ADULT VACCINATION TO DRIVE MARKET 138
9.4 HPV 142
9.4.1 EXPANDING NATIONAL HPV IMMUNIZATION PROGRAMS AND RISING ADOPTION OF GENDER-NEUTRAL VACCINATION TO DRIVE THE FASTEST-GROWING SEGMENT 142
9.5 HERPES ZOSTER 146
9.5.1 RISING AGING POPULATION TO DRIVE DEMAND FOR HERPES ZOSTER VACCINES 146
9.6 COMBINATION VACCINES 150
9.6.1 EXPANDING NATIONAL IMMUNIZATION PROGRAMS AND GROWING PREFERENCE FOR MULTI-ANTIGEN VACCINES TO DRIVE MARKET 150
9.7 MENINGOCOCCAL DISEASE 154
9.7.1 EXPANDING IMMUNIZATION RECOMMENDATIONS AND BROADER SEROGROUP COVERAGE TO SUPPORT MARKET GROWTH 154
9.8 ROTAVIRUS 158
9.8.1 RISING INFANT IMMUNIZATION PROGRAMS TO DRIVE ROTAVIRUS MARKET GROWTH 158
9.9 RSV 161
9.9.1 INITIAL VACCINE UPTAKE AND EXPANDING IMMUNIZATION RECOMMENDATIONS SUPPORT MARKET PENETRATION 161
9.10 DTP 165
9.10.1 CONTINUED ROUTINE CHILDHOOD IMMUNIZATION AND BOOSTER VACCINATION PROGRAMS TO SUPPORT MARKET 165
9.11 HEPATITIS 168
9.11.1 EXPANDING HEPATITIS B IMMUNIZATION AND GLOBAL ELIMINATION INITIATIVES TO SUPPORT MARKET GROWTH 168
9.12 VARICELLA 172
9.12.1 EXPANDING CHILDHOOD IMMUNIZATION PROGRAMS AND INCREASING ADOPTION OF VARICELLA VACCINES TO SUPPORT MARKET GROWTH 172
9.13 MMR 175
9.13.1 RISING MEASLES OUTBREAKS AND IMMUNIZATION RECOVERY EFFORTS TO SUPPORT MARKET GROWTH 175
9.14 POLIO 178
9.14.1 GLOBAL POLIO ERADICATION INITIATIVES AND CONTINUED VACCINATION CAMPAIGNS TO SUSTAIN MARKET DEMAND 178
9.15 COVID-19 181
9.15.1 SHIFT FROM PANDEMIC-DRIVEN DEMAND TO ENDURING HIGH-RISK POPULATION VACCINATION, RESULTING IN MARKET NORMALIZATION 181
9.16 OTHER DISEASE INDICATIONS 184
10 VACCINES MARKET, BY TECHNOLOGY 188
10.1 INTRODUCTION 189
10.2 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY 189
10.2.1 RECOMBINANT VACCINES 190
10.2.1.1 Broader adult immunization and continued recombinant vaccine launches to drive market 190
10.2.2 CONJUGATE VACCINES 193
10.2.2.1 Higher-valency pneumococcal vaccines and large public immunization programs to drive market 193
10.2.3 INACTIVATED & SUBUNIT VACCINES 196
10.2.3.1 Recurring influenza demand and wider access to established non-live vaccines to support market 196
10.2.4 LIVE ATTENUATED VACCINES 200
10.2.4.1 Durable immune protection and convenient oral or nasal administration to support market 200
10.2.5 TOXOID VACCINES 203
10.2.5.1 Routine pediatric boosters and maternal immunization programs to sustain market 203
10.2.6 OTHER VACCINES 206
10.3 COVID-19 VACCINES MARKET, BY TECHNOLOGY 210
10.3.1 MRNA VACCINES 210
10.3.1.1 Rapid variant adaptation and continued vaccination of high-risk populations to drive market 210
10.3.2 VIRAL VECTOR VACCINES 213
10.3.2.1 Withdrawal of first-generation products and shift toward updated vaccine platforms to accelerate market decline 213
10.3.3 OTHER COVID-19 VACCINES 216
11 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE 219
11.1 INTRODUCTION 220
11.2 MULTIVALENT VACCINES 220
11.2.1 BROADER SEROTYPE COVERAGE AND INCREASING ADOPTION OF COMBINATION IMMUNIZATION SCHEDULES TO DRIVE MARKET 220
11.3 MONOVALENT VACCINES 224
11.3.1 ESTABLISHED SINGLE-DISEASE PROGRAMS AND EXPANDING ADULT IMMUNIZATION INDICATIONS TO SUPPORT MARKET 224
12 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION 229
12.1 INTRODUCTION 230
12.2 INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION 230
12.2.1 EASE OF ABSORPTION AND BETTER IMMUNE RESPONSE TO DRIVE ADOPTION 230
12.3 ORAL ADMINISTRATION 234
12.3.1 NEEDLE-FREE DELIVERY AND HIGH-VOLUME DISEASE-CONTROL CAMPAIGNS TO SUPPORT MARKET 234
12.4 OTHER ROUTES OF ADMINISTRATION 237
13 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER 241
13.1 INTRODUCTION 242
13.2 ADULT VACCINES 242
13.2.1 AGING POPULATIONS, BROADER ADULT INDICATIONS, AND GROWING LIFE-COURSE IMMUNIZATION TO DRIVE MARKET 242
13.3 PEDIATRIC VACCINES 245
13.3.1 EXPANDING CHILDHOOD IMMUNIZATION SCHEDULES AND NEW VACCINE INTRODUCTIONS TO DRIVE MARKET GROWTH 245
14 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION 249
14.1 INTRODUCTION 250
14.2 NORTH AMERICA 250
14.2.1 US 254
14.2.1.1 US to dominate North American market during forecast period 254
14.2.2 CANADA 257
14.2.2.1 Expansion of life-course immunization to support market growth 257
14.3 EUROPE 260
14.3.1 GERMANY 263
14.3.1.1 Adult immunization and updated national recommendations to drive market growth 263
14.3.2 UK 266
14.3.2.1 Expansion of adult and maternal immunization programs to support market growth 266
14.3.3 FRANCE 269
14.3.3.1 Favorable government initiatives for mass immunization to drive market 269
14.3.4 ITALY 272
14.3.4.1 Higher investments by companies for increased production capacities to drive market 272
14.3.5 SPAIN 275
14.3.5.1 Rising investments in vaccine development by private organizations to drive market 275
14.3.6 REST OF EUROPE 277
14.4 ASIA PACIFIC 280
14.4.1 CHINA 284
14.4.1.1 China to hold largest share of APAC vaccines market 284
14.4.2 JAPAN 287
14.4.2.1 Aging population and gradual expansion of routine vaccination to drive demand 287
14.4.3 INDIA 290
14.4.3.1 Large immunization requirements and manufacturing leadership to support strong growth 290
14.4.4 SOUTH KOREA 293
14.4.4.1 Strong government strategies for improved vaccine hubs to drive market 293
14.4.5 REST OF ASIA PACIFIC 296
14.5 LATIN AMERICA 299
14.5.1 BRAZIL 302
14.5.1.1 Strong public procurement and domestic manufacturing to drive market 302
14.5.2 MEXICO 305
14.5.2.1 Trained workforce and ethnically varied population base for clinical trials to propel market growth 305
14.5.3 REST OF LATIN AMERICA 308
14.6 MIDDLE EAST 310
14.6.1 GOVERNMENT-LED LOCALIZATION AND EXPANDING ADULT AND TRAVEL IMMUNIZATION TO SUPPORT MARKET GROWTH 310
14.7 AFRICA 313
14.7.1 HIGH UNMET IMMUNIZATION NEEDS AND LOCAL MANUFACTURING INITIATIVES TO DRIVE MARKET EXPANSION 313
15 COMPETITIVE LANDSCAPE 317
15.1 OVERVIEW 317
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 317
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN VACCINES MARKET 317
15.3 REVENUE ANALYSIS, 2021–2025 319
15.4 MARKET SHARE ANALYSIS, 2025 320
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 322
15.5.1 STARS 323
15.5.2 EMERGING LEADERS 323
15.5.3 PERVASIVE PLAYERS 323
15.5.4 PARTICIPANTS 323
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 325
15.5.5.1 Company footprint 325
15.5.5.2 Region footprint 325
15.5.5.3 Technology footprint 326
15.5.5.4 Type footprint 327
15.5.5.5 Route of administration footprint 328
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 328
15.6.1 PROGRESSIVE COMPANIES 328
15.6.2 RESPONSIVE COMPANIES 329
15.6.3 DYNAMIC COMPANIES 329
15.6.4 STARTING BLOCKS 329
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 330
15.6.5.1 Detailed list of key startups/SMEs 330
15.6.5.2 Competitive benchmarking of key startups/SMEs 331
15.7 COMPANY VALUATION & FINANCIAL METRICS 332
15.7.1 FINANCIAL METRICS 332
15.7.2 COMPANY VALUATION 332
15.8 PRODUCT COMPARISON 333
15.8.1 PRODUCT COMPARATIVE ANALYSIS 333
15.9 COMPETITIVE SCENARIO 334
15.9.1 PRODUCT LAUNCHES & APPROVALS 334
15.9.2 DEALS 335
15.9.3 EXPANSIONS 336
16 COMPANY PROFILES 337
16.1 KEY PLAYERS 337
16.1.1 PFIZER INC. 337
16.1.1.1 Business overview 337
16.1.1.2 Products offered 338
16.1.1.3 Recent developments 340
16.1.1.3.1 Product approvals 340
16.1.1.4 MnM view 341
16.1.1.4.1 Key strengths 341
16.1.1.4.2 Strategic choices 341
16.1.1.4.3 Weaknesses & competitive threats 341
16.1.2 GSK PLC 342
16.1.2.1 Business overview 342
16.1.2.2 Products offered 343
16.1.2.3 Recent developments 345
16.1.2.3.1 Product launches & approvals 345
16.1.2.3.2 Deals 347
16.1.2.3.3 Expansions 347
16.1.2.4 MnM view 348
16.1.2.4.1 Key strengths 348
16.1.2.4.2 Strategic choices 348
16.1.2.4.3 Weaknesses & competitive threats 348
16.1.3 MERCK & CO., INC. 349
16.1.3.1 Business overview 349
16.1.3.2 Products offered 350
16.1.3.3 Recent developments 352
16.1.3.3.1 Product approvals 352
16.1.3.3.2 Expansions 353
16.1.3.4 MnM view 353
16.1.3.4.1 Key strengths 353
16.1.3.4.2 Strategic choices 353
16.1.3.4.3 Weaknesses & competitive threats 353
16.1.4 SANOFI 354
16.1.4.1 Business overview 354
16.1.4.2 Products offered 355
16.1.4.3 Recent developments 357
16.1.4.3.1 Product approvals 357
16.1.4.3.2 Deals 357
16.1.4.3.3 Expansions 358
16.1.4.3.4 Other developments 359
16.1.4.4 MnM view 359
16.1.4.4.1 Key strengths 359
16.1.4.4.2 Strategic choices 359
16.1.4.4.3 Weaknesses & competitive threats 359
16.1.5 CSL 360
16.1.5.1 Business overview 360
16.1.5.2 Products offered 361
16.1.5.3 Recent developments 362
16.1.5.3.1 Product approvals 362
16.1.5.3.2 Deals 362
16.1.5.3.3 Expansions 363
16.1.6 EMERGENT 364
16.1.6.1 Business overview 364
16.1.6.2 Products offered 365
16.1.6.3 Recent developments 366
16.1.6.3.1 Product approvals 366
16.1.6.3.2 Deals 367
16.1.6.3.3 Other developments 367
16.1.7 JOHNSON & JOHNSON SERVICES, INC. 368
16.1.7.1 Business overview 368
16.1.7.2 Products offered 369
16.1.7.3 Recent developments 370
16.1.7.3.1 Deals 370
16.1.8 ASTRAZENECA 371
16.1.8.1 Business overview 371
16.1.8.2 Products offered 372
16.1.8.3 Recent developments 373
16.1.8.3.1 Deals 373
16.1.8.3.2 Expansions 373
16.1.9 SERUM INSTITUTE OF INDIA PVT. LTD. 374
16.1.9.1 Business overview 374
16.1.9.2 Products offered 374
16.1.9.3 Recent developments 377
16.1.9.3.1 Product launches & approvals 377
16.1.9.3.2 Deals 378
16.1.9.3.3 Expansions 380
16.1.10 BAVARIAN NORDIC 381
16.1.10.1 Business overview 381
16.1.10.2 Products offered 382
16.1.10.3 Recent developments 383
16.1.10.3.1 Product approvals 383
16.1.10.3.2 Deals 384
16.1.10.3.3 Other developments 385
16.1.11 TANABE PHARMA CORPORATION 386
16.1.11.1 Business overview 386
16.1.11.2 Products offered 386
16.1.11.3 Recent developments 387
16.1.11.3.1 Product launches & approvals 387
16.1.11.3.2 Deals 387
16.1.12 DAIICHI SANKYO COMPANY, LIMITED 388
16.1.12.1 Business overview 388
16.1.12.2 Products offered 389
16.1.12.3 Recent developments 390
16.1.12.3.1 Deals 390
16.1.13 PANACEA BIOTEC 391
16.1.13.1 Business overview 391
16.1.13.2 Products offered 392
16.1.13.3 Recent developments 393
16.1.13.3.1 Other developments 393
16.1.14 BIOLOGICAL E. LIMITED 394
16.1.14.1 Business overview 394
16.1.14.2 Products offered 394
16.1.14.3 Recent developments 396
16.1.14.3.1 Product approvals 396
16.1.14.3.2 Deals 397
16.1.14.3.3 Other developments 397
16.1.15 BHARAT BIOTECH 398
16.1.15.1 Business overview 398
16.1.15.2 Products offered 398
16.1.15.3 Recent developments 399
16.1.15.3.1 Product launches & approvals 399
16.1.15.3.2 Deals 400
16.1.16 NOVAVAX 401
16.1.16.1 Business overview 401
16.1.16.2 Products offered 402
16.1.16.3 Recent developments 402
16.1.16.3.1 Product approvals 402
16.1.16.3.2 Deals 403
16.1.17 INOVIO PHARMACEUTICALS 404
16.1.17.1 Business overview 404
16.1.17.2 Products offered 405
16.1.17.3 Recent developments 405
16.1.17.3.1 Other developments 405
16.2 OTHER PLAYERS 406
16.2.1 SINOVAC 406
16.2.2 INCEPTA PHARMACEUTICALS LTD. 408
16.2.3 VALNEVA SE 410
16.2.4 EUBIOLOGICS CO., LTD. 411
16.2.5 BIO FARMA 412
16.2.6 MICROGEN 414
16.2.7 CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. 415
16.2.8 INDIAN IMMUNOLOGICALS LIMITED 416
17 RESEARCH METHODOLOGY 417
17.1 RESEARCH DATA 417
17.1.1 SECONDARY DATA 418
17.1.1.1 Key secondary sources 418
17.1.1.2 Key data from secondary research 418
17.1.2 PRIMARY DATA 419
17.1.2.1 Key primary participants 419
17.1.2.2 Breakdown of primary interviews 419
17.1.2.3 Key data from primary sources 420
17.2 MARKET SIZE ESTIMATION 420
17.2.1 GLOBAL VACCINES MARKET SIZE ESTIMATION, 2025 420
17.2.1.1 Approach 1: Company revenue analysis-based estimation (bottom-up approach) 421
17.2.1.2 Approach 2: Primary research 422
17.2.1.2.1 Key industry insights 423
17.2.1.3 Approach 3: Secondary analysis 423
17.2.1.4 Approach 4: Bottom-up approach (disease indication-based analysis) 423
17.2.1.5 Approach 5: MarketsandMarkets repository analysis 424
17.2.2 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH), 2025 424
17.3 MARKET GROWTH RATE PROJECTIONS 426
17.4 DATA TRIANGULATION 428
17.5 RESEARCH ASSUMPTIONS 429
17.6 RESEARCH LIMITATIONS & RISK ASSESSMENT 431
18 APPENDIX 432
18.1 DISCUSSION GUIDE 432
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 436
18.3 CUSTOMIZATION OPTIONS 438
18.4 RELATED REPORTS 438
18.5 AUTHOR DETAILS 439

ページTOPに戻る

List of Tables/Graphs

TABLE 1 VACCINES MARKET: INCLUSIONS & EXCLUSIONS 41.
TABLE 2 VACCINES MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 56.
TABLE 3 NIH FUNDING FOR VACCINE RESEARCH, 2020–2025 (USD MILLION) 62.
TABLE 4 MAJOR COST DRIVERS AND IMPACT ON COST OF GOODS SOLD (COGS) 62.
TABLE 5 NOTABLE CANCER VACCINES IN CLINICAL TRIALS 66.
TABLE 6 VACCINES MARKET: IMPACT OF PORTER’S FIVE FORCES 72.
TABLE 7 VACCINE PIPELINE PRODUCTS UNDER PHASE 3 CLINICAL TRIALS FOR RSV 78.
TABLE 8 VACCINE PIPELINE PRODUCTS UNDER PHASE 3 CLINICAL TRIALS FOR CANCER 80.
TABLE 9 VACCINE PIPELINE PRODUCTS UNDER PHASE 3 CLINICAL TRIALS FOR INFLUENZA 80.
TABLE 10 KEY PIPELINE VACCINES: GSK PLC 81.
TABLE 11 KEY PIPELINE VACCINES: MERCK & CO., INC. 82.
TABLE 12 KEY PIPELINE VACCINES: PFIZER INC. 82.
TABLE 13 KEY PIPELINE VACCINES: SANOFI 83.
TABLE 14 VACCINES MARKET: ROLE IN ECOSYSTEM 84.
TABLE 15 AVERAGE SELLING PRICE TREND OF PEDIATRIC VACCINES, BY KEY PLAYER, 2024–2026 (USD) 86.
TABLE 16 AVERAGE SELLING PRICE TREND OF ADULT VACCINES, BY KEY PLAYER, 2024–2026 (USD) 87.
TABLE 17 AVERAGE SELLING PRICE TREND OF VACCINES, BY REGION, 2022–2024 (USD) 89.
TABLE 18 IMPORT DATA FOR HS CODE 300220, 2021–2025 (USD THOUSAND) 91.
TABLE 19 IMPORT DATA FOR HS CODE 300220, 2021–2025 (TONS) 92.
TABLE 20 EXPORT DATA FOR HS CODE 300220, 2021–2025 (USD THOUSAND) 93.
TABLE 21 EXPORT DATA FOR HS CODE 300220, 2021–2025 (TONS) 93.
TABLE 22 VACCINES MARKET: KEY CONFERENCES AND EVENTS, 2026–2027 94.
TABLE 23 US ADJUSTED RECIPROCAL TARIFF RATES 98.
TABLE 24 NUMBER OF VACCINES DELIVERED BY UNICEF, 2024–2026 101.
TABLE 25 WHO VACCINE PURCHASE DATABASE, BY PROCUREMENT MECHANISM, 2022–2024 102.
TABLE 26 WHO VACCINE PURCHASE DATABASE, BY MANUFACTURER, 2022–2024 103.
TABLE 27 WHO VACCINE PURCHASE DATABASE, BY INDICATION, 2022–2024 103.
TABLE 28 WHO VACCINE PURCHASE DATABASE, BY REGION, 2022–2024 104.
TABLE 29 VACCINE PRODUCTION CAPACITY, BY KEY PLAYER, 2025 105.
TABLE 30 KEY VACCINE MANUFACTURING CAPACITY EXPANSIONS, 2025–2026 106.
TABLE 31 VACCINES MARKET: INDICATIVE LIST OF PATENTS, 2026 112.
TABLE 32 CASE STUDIES OF AI IMPLEMENTATION IN VACCINES MARKET 117.
TABLE 33 CLIENT’S READINESS TO ADOPT GENERATIVE AI IN VACCINES 118.
TABLE 34 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 119.
TABLE 35 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 120.
TABLE 36 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 121.
TABLE 37 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 121.
TABLE 38 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY VACCINES 128.
TABLE 39 KEY BUYING CRITERIA, BY END USER 129.
TABLE 40 VACCINES MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 133.
TABLE 41 LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL DISEASE VACCINES 135.
TABLE 42 PNEUMOCOCCAL DISEASE VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 136.
TABLE 43 NORTH AMERICA: PNEUMOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 136.
TABLE 44 EUROPE: PNEUMOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 137.
TABLE 45 ASIA PACIFIC: PNEUMOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 137.
TABLE 46 LATIN AMERICA: PNEUMOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 138.
TABLE 47 LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES 139.
TABLE 48 INFLUENZA VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 140.
TABLE 49 NORTH AMERICA: INFLUENZA VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 140.
TABLE 50 EUROPE: INFLUENZA VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 141.
TABLE 51 ASIA PACIFIC: INFLUENZA VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 141.
TABLE 52 LATIN AMERICA: INFLUENZA VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 142.
TABLE 53 LIST OF COMMERCIALLY AVAILABLE HPV VACCINES 143.
TABLE 54 HPV VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 144.
TABLE 55 NORTH AMERICA: HPV VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 144.
TABLE 56 EUROPE: HPV VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 145.
TABLE 57 ASIA PACIFIC: HPV VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 145.
TABLE 58 LATIN AMERICA: HPV VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 146.
TABLE 59 LIST OF COMMERCIALLY AVAILABLE HERPES ZOSTER VACCINES 147.
TABLE 60 HERPES ZOSTER VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 148.
TABLE 61 NORTH AMERICA: HERPES ZOSTER VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148.
TABLE 62 EUROPE: HERPES ZOSTER VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 149.
TABLE 63 ASIA PACIFIC: HERPES ZOSTER VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 149.
TABLE 64 LATIN AMERICA: HERPES ZOSTER VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150.
TABLE 65 LIST OF COMMERCIALLY AVAILABLE COMBINATION VACCINES 151.
TABLE 66 COMBINATION VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 152.
TABLE 67 NORTH AMERICA: COMBINATION VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 152.
TABLE 68 EUROPE: COMBINATION VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 153.
TABLE 69 ASIA PACIFIC: COMBINATION VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 153.
TABLE 70 LATIN AMERICA: COMBINATION VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 154.
TABLE 71 LIST OF COMMERCIALLY AVAILABLE MENINGOCOCCAL DISEASE VACCINES 155.
TABLE 72 MENINGOCOCCAL DISEASE VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 155.
TABLE 73 NORTH AMERICA: MENINGOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 156.
TABLE 74 EUROPE: MENINGOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 156.
TABLE 75 ASIA PACIFIC: MENINGOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 157.
TABLE 76 LATIN AMERICA: MENINGOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 157.
TABLE 77 LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES 158.
TABLE 78 ROTAVIRUS VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 159.
TABLE 79 NORTH AMERICA: ROTAVIRUS VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 159.
TABLE 80 EUROPE: ROTAVIRUS VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 160.
TABLE 81 ASIA PACIFIC: ROTAVIRUS VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 160.
TABLE 82 LATIN AMERICA: ROTAVIRUS VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 161.
TABLE 83 LIST OF COMMERCIALLY AVAILABLE RSV VACCINES 162.
TABLE 84 RSV VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 163.
TABLE 85 NORTH AMERICA: RSV VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 163.
TABLE 86 EUROPE: RSV VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 164.
TABLE 87 ASIA PACIFIC: RSV VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 164.
TABLE 88 LATIN AMERICA: RSV VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 165.
TABLE 89 LIST OF COMMERCIALLY AVAILABLE DTP VACCINES 165.
TABLE 90 DTP VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 166.
TABLE 91 NORTH AMERICA: DTP VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 166.
TABLE 92 EUROPE: DTP VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 167.
TABLE 93 ASIA PACIFIC: DTP VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 167.
TABLE 94 LATIN AMERICA: DTP VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 168.
TABLE 95 LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES 169.
TABLE 96 HEPATITIS VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 169.
TABLE 97 NORTH AMERICA: HEPATITIS VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 170.
TABLE 98 EUROPE: HEPATITIS VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 170.
TABLE 99 ASIA PACIFIC: HEPATITIS VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 171.
TABLE 100 LATIN AMERICA: HEPATITIS VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 171.
TABLE 101 LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES 172.
TABLE 102 VARICELLA VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 173.
TABLE 103 NORTH AMERICA: VARICELLA VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 173.
TABLE 104 EUROPE: VARICELLA VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 174.
TABLE 105 ASIA PACIFIC: VARICELLA VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 174.
TABLE 106 LATIN AMERICA: VARICELLA VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 175.
TABLE 107 TOP 10 COUNTRIES WITH MEASLES OUTBREAKS, JANUARY 2025–JULY 2025 175.
TABLE 108 LIST OF COMMERCIALLY AVAILABLE MMR VACCINES 176.
TABLE 109 MMR VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 176.
TABLE 110 NORTH AMERICA: MMR VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 177.
TABLE 111 EUROPE: MMR VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 177.
TABLE 112 ASIA PACIFIC: MMR VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 178.
TABLE 113 LATIN AMERICA: MMR VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 178.
TABLE 114 POLIO VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 179.
TABLE 115 NORTH AMERICA: POLIO VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 179.
TABLE 116 EUROPE: POLIO VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 180.
TABLE 117 ASIA PACIFIC: POLIO VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 180.
TABLE 118 LATIN AMERICA: POLIO VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 181.
TABLE 119 COVID-19 VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 182.
TABLE 120 NORTH AMERICA: COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 182.
TABLE 121 EUROPE: COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 183.
TABLE 122 ASIA PACIFIC: COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 183.
TABLE 123 LATIN AMERICA: COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 184.
TABLE 124 LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS 185.
TABLE 125 VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2024–2031 (USD MILLION) 185.
TABLE 126 NORTH AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 186.
TABLE 127 EUROPE: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 186.
TABLE 128 ASIA PACIFIC: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 187.
TABLE 129 LATIN AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 187.
TABLE 130 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 189.
TABLE 131 EXAMPLES OF RECOMBINANT VACCINES 190.
TABLE 132 RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION) 191.
TABLE 133 NORTH AMERICA: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 191.
TABLE 134 EUROPE: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 192.
TABLE 135 ASIA PACIFIC: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 192.
TABLE 136 LATIN AMERICA: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 193.
TABLE 137 EXAMPLES OF CONJUGATE VACCINES 194.
TABLE 138 CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION) 194.
TABLE 139 NORTH AMERICA: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 195.
TABLE 140 EUROPE: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 195.
TABLE 141 ASIA PACIFIC: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 196.
TABLE 142 LATIN AMERICA: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 196.
TABLE 143 EXAMPLES OF INACTIVATED & SUBUNIT VACCINES 197.
TABLE 144 INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION) 198.
TABLE 145 NORTH AMERICA: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 198.
TABLE 146 EUROPE: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 199.
TABLE 147 ASIA PACIFIC: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 199.
TABLE 148 LATIN AMERICA: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 200.
TABLE 149 EXAMPLES OF LIVE ATTENUATED VACCINES 201.
TABLE 150 LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION) 201.
TABLE 151 NORTH AMERICA: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 202.
TABLE 152 EUROPE: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 202.
TABLE 153 ASIA PACIFIC: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 203.
TABLE 154 LATIN AMERICA: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 203.
TABLE 155 EXAMPLES OF TOXOID VACCINES 204.
TABLE 156 TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION) 204.
TABLE 157 NORTH AMERICA: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 205.
TABLE 158 EUROPE: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 205.
TABLE 159 ASIA PACIFIC: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 206.
TABLE 160 LATIN AMERICA: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 206.
TABLE 161 OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION) 207.
TABLE 162 NORTH AMERICA: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 208.
TABLE 163 EUROPE: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 208.
TABLE 164 ASIA PACIFIC: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 209.
TABLE 165 LATIN AMERICA: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 209.
TABLE 166 COVID-19 VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 210.
TABLE 167 MRNA COVID-19 VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 211.
TABLE 168 NORTH AMERICA: MRNA COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 212.
TABLE 169 EUROPE: MRNA COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 212.
TABLE 170 ASIA PACIFIC: MRNA COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 213.
TABLE 171 LATIN AMERICA: MRNA COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 213.
TABLE 172 VIRAL VECTOR COVID-19 VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 214.
TABLE 173 NORTH AMERICA: VIRAL VECTOR COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 214.
TABLE 174 EUROPE: VIRAL VECTOR COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 215.
TABLE 175 ASIA PACIFIC: VIRAL VECTOR COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 215.
TABLE 176 LATIN AMERICA: VIRAL VECTOR COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 216.
TABLE 177 OTHER COVID-19 VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 216.
TABLE 178 NORTH AMERICA: OTHER COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 217.
TABLE 179 EUROPE: OTHER COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 217.
TABLE 180 ASIA PACIFIC: OTHER COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 218.
TABLE 181 LATIN AMERICA: OTHER COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 218.
TABLE 182 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 220.
TABLE 183 EXAMPLES OF MULTIVALENT VACCINES 221.
TABLE 184 MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION) 222.
TABLE 185 NORTH AMERICA: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 222.
TABLE 186 EUROPE: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 223.
TABLE 187 ASIA PACIFIC: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 223.
TABLE 188 LATIN AMERICA: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 224.
TABLE 189 EXAMPLES OF MONOVALENT VACCINES 225.
TABLE 190 MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION) 226.
TABLE 191 NORTH AMERICA: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 226.
TABLE 192 EUROPE: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 227.
TABLE 193 ASIA PACIFIC: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 227.
TABLE 194 LATIN AMERICA: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 228.
TABLE 195 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 230.
TABLE 196 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION 231.
TABLE 197 VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION) 232.
TABLE 198 NORTH AMERICA: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 232.
TABLE 199 EUROPE: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 233.
TABLE 200 ASIA PACIFIC: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 233.
TABLE 201 LATIN AMERICA: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 234.
TABLE 202 VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION) 235.
TABLE 203 NORTH AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 235.
TABLE 204 EUROPE: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 236.
TABLE 205 ASIA PACIFIC: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 236.
TABLE 206 LATIN AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 237.
TABLE 207 VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION) 238.
TABLE 208 NORTH AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 238.
TABLE 209 EUROPE: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 239.
TABLE 210 ASIA PACIFIC: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 239.
TABLE 211 LATIN AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 240.
TABLE 212 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 242.
TABLE 213 ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION) 243.
TABLE 214 NORTH AMERICA: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 244.
TABLE 215 EUROPE: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 244.
TABLE 216 ASIA PACIFIC: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 245.
TABLE 217 LATIN AMERICA: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 245.
TABLE 218 PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION) 246.
TABLE 219 NORTH AMERICA: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 247.
TABLE 220 EUROPE: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 247.
TABLE 221 ASIA PACIFIC: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 248.
TABLE 222 LATIN AMERICA: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 248.
TABLE 223 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION) 250.
TABLE 224 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 252.
TABLE 225 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 252.
TABLE 226 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 253.
TABLE 227 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 253.
TABLE 228 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 254.
TABLE 229 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 254.
TABLE 230 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 255.
TABLE 231 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 256.
TABLE 232 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 256.
TABLE 233 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 257.
TABLE 234 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 257.
TABLE 235 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 258.
TABLE 236 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 258.
TABLE 237 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 259.
TABLE 238 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 259.
TABLE 239 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 260.
TABLE 240 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 261.
TABLE 241 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 261.
TABLE 242 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 262.
TABLE 243 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 262.
TABLE 244 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 263.
TABLE 245 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 263.
TABLE 246 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 264.
TABLE 247 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 265.
TABLE 248 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 265.
TABLE 249 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 266.
TABLE 250 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 266.
TABLE 251 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 267.
TABLE 252 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 267.
TABLE 253 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 268.
TABLE 254 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 268.
TABLE 255 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 269.
TABLE 256 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 270.
TABLE 257 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 270.
TABLE 258 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 271.
TABLE 259 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 271.
TABLE 260 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 272.
TABLE 261 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 273.
TABLE 262 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 273.
TABLE 263 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 274.
TABLE 264 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 274.
TABLE 265 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 275.
TABLE 266 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 275.
TABLE 267 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 276.
TABLE 268 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 276.
TABLE 269 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 277.
TABLE 270 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 277.
TABLE 271 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 278.
TABLE 272 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 278.
TABLE 273 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 279.
TABLE 274 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 279.
TABLE 275 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 280.
TABLE 276 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 281.
TABLE 277 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 282.
TABLE 278 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 282.
TABLE 279 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 283.
TABLE 280 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 283.
TABLE 281 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 284.
TABLE 282 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 285.
TABLE 283 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 285.
FIGURE 1 VACCINES MARKET SEGMENTATION & REGIONS COVERED 40.
FIGURE 2 MARKET SCENARIO 44.
FIGURE 3 GLOBAL VACCINES MARKET (INCLUDING COVID-19 VACCINES), 2024–2031 45.
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN VACCINES MARKET, 2023–2026 46.
FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF VACCINES MARKET 47.
FIGURE 6 HIGH-GROWTH SEGMENTS IN VACCINES MARKET (EXCLUDING COVID-19 VACCINES), 2026–2031 48.
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN VACCINES MARKET (EXCLUDING COVID-19 VACCINES), IN TERMS OF VALUE, DURING FORECAST PERIOD 49.
FIGURE 8 FOCUS ON VACCINE DEVELOPMENT AND LAUNCHES TO DRIVE MARKET GROWTH 51.
FIGURE 9 US AND MULTIVALENT VACCINES ACCOUNTED FOR THE LARGEST SHARE OF THE VACCINES MARKET IN NORTH AMERICA IN 2025 52.
FIGURE 10 ASIA PACIFIC IS LIKELY TO BE FASTEST-GROWING MARKET DURING 2026–2031 53.
FIGURE 11 INTRAMUSCULAR AND SUBCUTANEOUS ROUTE TO DOMINATE MARKET DURING FORECAST PERIOD 54.
FIGURE 12 VACCINES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 55.
FIGURE 13 US: NOVEL INFLUENZA A VIRUS CASES, BY SEASON (2010–2011 TO 2025–2026 SEASON) 58.
FIGURE 14 MANUFACTURING-RELATED PARAMETERS INCLUDED IN COST MODEL 64.
FIGURE 15 US: ESTIMATED NUMBER OF NEW CANCER CASES AND DEATHS BY SITE, 2025 65.
FIGURE 16 VACCINES MARKET: PORTER’S FIVE FORCES ANALYSIS 72.
FIGURE 17 GLOBAL GDP GROWTH, 2020–2030 75.
FIGURE 18 VACCINES MARKET: VALUE CHAIN ANALYSIS 76.
FIGURE 19 VACCINES MARKET: CLINICAL TRIALS, BY PHASE 77.
FIGURE 20 VACCINES MARKET: CLINICAL TRIALS, BY DISEASE INDICATION 78.
FIGURE 21 VACCINES MARKET ECOSYSTEM 84.
FIGURE 22 AVERAGE SELLING PRICE TREND OF VACCINES, BY DISEASE INDICATION, 2024–2026 (USD) 88.
FIGURE 23 REVENUE SHIFT AND NEW REVENUE POCKETS FOR PLAYERS IN VACCINES MARKET 96.
FIGURE 24 VACCINES MARKET: PHARMACEUTICAL M&A DEAL ACTIVITY, NUMBER, AND AGGREGATE TOTAL VALUE, 2021–2025 97.
FIGURE 25 TOP APPLICANTS/OWNERS (COMPANIES) FOR VACCINE PATENTS, 2015–2025 112.
FIGURE 26 IMPACT OF AI/GEN AI ON VACCINES MARKET 116.
FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VACCINES 127.
FIGURE 28 KEY BUYING CRITERIA, BY END USER 129.
FIGURE 29 NORTH AMERICA: VACCINES MARKET SNAPSHOT (EXCLUDING COVID-19 VACCINES) 251.
FIGURE 30 ASIA PACIFIC: VACCINES MARKET SNAPSHOT (EXCLUDING COVID-19 VACCINES) 281.
FIGURE 31 REVENUE ANALYSIS OF KEY PLAYERS IN VACCINES MARKET, 2021–2025 (USD BILLION) 320.
FIGURE 32 MARKET SHARE ANALYSIS OF KEY PLAYERS IN VACCINES MARKET, 2025 321.
FIGURE 33 VACCINES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 324.
FIGURE 34 VACCINES MARKET: COMPANY FOOTPRINT 325.
FIGURE 35 VACCINES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 329.
FIGURE 36 EV/EBITDA OF KEY VENDORS 332.
FIGURE 37 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 332.
FIGURE 38 VACCINES MARKET: PRODUCT COMPARATIVE ANALYSIS 333.
FIGURE 39 PFIZER INC.: COMPANY SNAPSHOT (2025) 338.
FIGURE 40 GSK PLC: COMPANY SNAPSHOT (2025) 343.
FIGURE 41 MERCK & CO., INC.: COMPANY SNAPSHOT (2025) 350.
FIGURE 42 SANOFI: COMPANY SNAPSHOT (2025) 355.
FIGURE 43 CSL: COMPANY SNAPSHOT (2025) 361.
FIGURE 44 EMERGENT: COMPANY SNAPSHOT (2025) 365.
FIGURE 45 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2025) 369.
FIGURE 46 ASTRAZENECA: COMPANY SNAPSHOT (2025) 372.
FIGURE 47 BAVARIAN NORDIC: COMPANY SNAPSHOT (2025) 382.
FIGURE 48 DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2025) 389.
FIGURE 49 PANACEA BIOTEC: COMPANY SNAPSHOT (2024) 392.
FIGURE 50 NOVAVAX: COMPANY SNAPSHOT (2025) 401.
FIGURE 51 INOVIO PHARMACEUTICALS: COMPANY SNAPSHOT (2025) 404.
FIGURE 52 VACCINES MARKET: RESEARCH DESIGN 417.
FIGURE 53 VACCINES MARKET: BREAKDOWN OF PRIMARIES 419.
FIGURE 54 GLOBAL VACCINES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025 420.
FIGURE 55 GLOBAL VACCINES MARKET: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH), 2025 421.
FIGURE 56 ILLUSTRATIVE EXAMPLE OF PFIZER INC.: REVENUE ANALYSIS, 2025 422.
FIGURE 57 VACCINES MARKET: INSIGHTS FROM PRIMARIES 423.
FIGURE 58 ILLUSTRATIVE EXAMPLE OF INFLUENZA VACCINES: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH), 2025 424.
FIGURE 59 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 425.
FIGURE 60 VACCINES MARKET: CAGR PROJECTIONS 427.
FIGURE 61 VACCINES MARKET: DATA TRIANGULATION 429.